Search clinical trials for: HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]

Total 120 results

Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

A Study to Assess the Tolerability, Safety, and Pharmacokinetics of Subcutaneous Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) With Ramp-up and No Ramp-up Dosing in Healthy Adult Participants

Healthy Volunteers

United States
Baxalta now part of Shire
Takeda Development Center Americas, Inc.

Completed

Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Spain, Canada, Poland, Italy, Serbia, Germany, Mexico, Turkey, United Kingdom, Czechia, France, United States, Argentina, Brazil, Colombia, Denmark, Greece, Slovakia
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

Pregnancy Registry to Collect Long-Term Safety Data From Women Treated With HyQvia

Exposure During Pregnancy

Poland, Czechia, United States, Germany, Slovakia
Takeda
Takeda Development Center Americas, Inc.

Recruiting

A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases

Primary Immunodeficiency Diseases (PID)

United States
Baxalta now part of Shire

Completed

Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously

Primary Immunodeficiency Diseases (PID)

United States
Baxalta now part of Shire

Completed

Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD

Primary Immunodeficiency Diseases (PID)

United States
Takeda

Completed

A Study of TAK-771 in Japanese People With Primary Immunodeficiency Diseases (PID)

Primary Immunodeficiency Diseases (PID)

Japan
Baxalta now part of Shire
Takeda Development Center Americas, Inc.

Completed

A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

United States, Israel, Canada, Spain, Czechia, Croatia, Poland, Italy, Serbia, Germany, Argentina, Mexico, Turkey, United Kingdom, Brazil, France, Greece, Slovakia, Colombia, Denmark, Norway, Sweden
Takeda

Active, not recruiting

A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants

Primary Immunodeficiency Diseases (PID)

Japan
Takeda

Active, not recruiting

A Study of TAK-771 in Japanese Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN)

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | Multifocal Motor Neuropathy (MMN)

Japan
Baxalta now part of Shire

Completed

Gammagard Liquid and rHuPH20 in PID

Primary Immunodeficiency Diseases (PID)

United States, Canada
Takeda
Takeda Development Center Americas, Inc.

Not yet recruiting

A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases

Primary Immunodeficiency Diseases (PID)
Takeda
Takeda Development Center Americas, Inc.; Baxalta Innovations GmbH, now part...

Completed

A Study of TAK-881 in Healthy Adults

Healthy Volunteers

United States
GWT-TUD GmbH

Completed

Facilitated Immunoglobulin Administration Registry and Outcomes Study (FIGARO) (FIGARO)

Primary Immunodeficiency | Secondary Immune Deficiency

Germany, Italy, France
Massachusetts General Hospital
Baxter Healthcare Corporation

Completed

EASI Access II --- Follow-up Study to the EASI Access Trial

Disaster Medicine | Dehydration | Difficult Intravenous Access

United States
Baxalta now part of Shire

Completed

Phase 2/3 Study of IGSC, 20% in PIDD

Primary Immunodeficiency Diseases (PID)

United States, Canada
Baxalta now part of Shire

Terminated

Phase 3 IGIV, 10% in Alzheimer´s Disease

Alzheimer´s Disease

United States, Poland, United Kingdom, Belgium, Spain, Japan, Canada, Australia
Biotest Pharmaceuticals Corporation

Completed

Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.

Liver Cirrhosis | Hepatitis, Viral, Human | Hepatocellular Carcinoma | Hepatitis C Infection | Viruses

United States
Baxalta now part of Shire
Alzheimer's Disease Cooperative Study (ADCS)

Completed

A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease

Alzheimer´s Disease

United States, Canada
Baxalta now part of Shire

Completed

Study of the Effectiveness of Intravenous Immune Globulin (10%) for the Treatment of Multifocal Motor Neuropathy

Multifocal Motor Neuropathy

United States, Canada, Denmark
Baxalta now part of Shire

Completed

Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects

Primary Immunodeficiency Diseases (PID)

United States
National Institute of Allergy and Infectious Diseases...

Terminated

Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%

Kidney Failure, Chronic

United States
Baxalta now part of Shire

Completed

A Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Participants With Primary Immunodeficiency Diseases (PID)

Primary Immunodeficiency Diseases (PID)

Japan
ADMA Biologics, Inc.

Completed

Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)

Primary Immune Deficiency Disorders (PIDD)

United States
Green Cross Corporation
Atlantic Research Group

Recruiting

Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency

Primary Immune Deficiency

United States
Baxalta now part of Shire

Completed

Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders

Primary Immunodeficiency Diseases (PID) | Immune Thrombocytopenic Purpura (ITP) | Kawasaki Syndrome

United States
Baxalta now part of Shire

Completed

Immune Globulin Subcutaenous (Human), 20%

Primary Immunodeficiency Diseases (PID)

Germany, Austria, Hungary, Sweden, United Kingdom
Inova Health Care Services
CSL Behring

Withdrawn

IVIG in Acute Ischemic Stroke: A Pilot Study (IVIG/AIS)

Ischemic Stroke

United States
Grifols Therapeutics LLC

Completed

Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients

Common Variable Immunodeficiency | Severe Combined Immunodeficiency | Wiskott-Aldrich Syndrome | Agammaglobulinemia | Immunologic Deficiency Syndrome

Canada, United States
University of Chicago
Sunnybrook Health Sciences Centre; University of British Columbia; University... and other collaborators

Completed

Intravenous Immunoglobulin (IVIG) for Treatment of Unexplained Secondary Recurrent Miscarriage

Abortion, Habitual | Miscarriage, Recurrent

United States
University of Southern California
National Cancer Institute (NCI); Genentech, Inc.

Recruiting

Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung... and other conditions

United States
Baxalta now part of Shire

Terminated

Long-Term Study of IGIV, 10% in Alzheimer´s Disease

Alzheimer´s Disease

United States
Halozyme Therapeutics

Completed

CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)

Type 1 Diabetes Mellitus

United States
Biotest
Syneos Health

Completed

Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID

Primary Immunodeficiency Disease

United States, Germany, Hungary, Russian Federation, Spain
Green Cross Corporation
Parexel; Atlantic Research Group

Completed

Study of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency

Immunologic Deficiency Syndromes

Canada, United States
Baxalta now part of Shire

Completed

Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PID

Primary Immunodeficiency Diseases (PID)

United States
Grifols Therapeutics LLC

Completed

Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP

Purpura, Thrombocytopenic, Idiopathic

United States
Takeda

Completed

An Extension Study of TAK-664 for Japanese People With Primary Immunodeficiency Disease

Primary Immunodeficiency Disease

Japan
Baxalta now part of Shire

Completed

Efficacy and Safety Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Adult Subjects With Chronic Idiopathic Thrombocytopenic Purpura

Immune Thrombocytopenic Purpura (ITP)

Poland, Hungary, Germany, Czechia
Halozyme Therapeutics

Completed

Pharmacokinetic (PK), Pharmacodynamic (PD), and Safety Study of Subcutaneously Administered Humalog® With and Without Recombinant Human Hyaluronidase (rHuPH20)and Humulin-R® With and Without rHuPH20

Diabetes Mellitus

United States
Peking University Cancer Hospital & Institute

Active, not recruiting

Clinical Study to Evaluate OrienX010 in Combination With Toripalimab as Neoadjuvant Treatment in Advanced Melanoma

Melanoma

China
Halozyme Therapeutics

Completed

Pharmacokinetic and Glucodynamic Crossover Study of Subcutaneously (SC) Administered Insulin Lispro + Recombinant Human Hyaluronidase (rHuPH20) and Regular Human Insulin + rHuPH20 Compared to Insulin Lispro Alone

Diabetes Mellitus

United States
Halozyme Therapeutics

Completed

Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH20 in Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

United States
Baxalta now part of Shire

Completed

Safety, Pharmacokinetic and Efficacy Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Patients With Primary Immunodeficiency (Hypo- or Agammaglobulinemia)

Primary Immunodeficiency Diseases (PID) | Hypogammaglobulinemia | Agammaglobulinemia

Finland, Sweden
Academisch Medisch Centrum - Universiteit van Amsterdam...
Princess Beatrix Muscle Foundation

Recruiting

Add-on Intravenous Immunoglobulins in Early Myositis (TIMEISMUSCLE)

Myositis | Dermatomyositis | Polymyositis | Antisynthetase Syndrome | Immune-Mediated Necrotizing Myopathy | Inflammatory Myopathy, Idiopathic

Netherlands
Halozyme Therapeutics

Completed

Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 (rHuPH20) and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Participants With Type 2 Diabetes Mellitus (T2DM)

Diabetes Mellitus, Type 2

United States
Beijing VDJBio Co., LTD.

Recruiting

Clinical Study of Recombinant Humanized CTLA-4-FC Fusion Protein Injection in Healthy Subjects

Health Volunteer

China
Thomas Jefferson University
Janssen Scientific Affairs, LLC

Active, not recruiting

Home Based Daratumumab Administration for Patients With Multiple Myeloma

Plasma Cell Myeloma

United States
Grifols Therapeutics LLC

Completed

Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis (PRIVIG)

Multiple Sclerosis, Relapsing-Remitting

Canada, Israel, United States, Austria, Czech Republic, Germany, Greece, Hungary, Poland, Slovakia, Sweden, United Kingdom
Halozyme Therapeutics

Completed

Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus

Diabetes Mellitus, Type 1

United States

Search clinical trials for: HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Togo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations